logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
A

Aaron S. Kesselheim

Department of Medicine

76H指数
1.0K论文数
2.4W被引数
收录论文 590
发表时间
logo
Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study美国医疗保险处方药的最惠国定价：一项队列研究
errThe Lancet
IF88.5
err2026-09-13
err0
PREAI
errThomas J Hwang; Simon Hediger; Advaita Krishnan; Christopher L Cai; Aaron S Kesselheim; Kerstin Noelle Vokinger
err分享
err收藏
Communicating Drug Safety and Safe Use Conditions in Risk Evaluation and Mitigation Strategy Materials在风险评价和缓解策略材料中传达药物安全性和安全使用条件
errDrug Safety
IF3.8
err2026-09-02
err0
PREAI
errAmeet Sarpatwari; Frazer A. Tessema; Mayookha Mitra-Majumdar; Su Been Lee; Heidi Zakoul; Beatrice L. Brown; Gita A. Toyserkani; Kate Heinrich Oswell; Cynthia LaCivita; Gerald J. Dal Pan; Steven Woloshin; Jerry Avorn; Aaron S. Kesselheim
err分享
err收藏
Realizing Benefits of First-in-Class Generic Entry—The Case of SGLT2 Inhibitors实现首仿药进入的效益——SGLT2抑制剂案例
errCLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
err2026-08-29
err0
PREAI
errSuhas Gondi; Aaron S. Kesselheim; Benjamin N. Rome
err分享
err收藏
Money, Meals, and Marketing in Medicine: A 13-Year Follow-Up Survey of Physicians金钱、餐饮与医药营销：一项对医生的13年随访调查
errCLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
err2026-08-11
err0
PREAI
errHelen Mooney; Kirsten Austad; Eric G. Campbell; Jerry Avorn; Zhigang Lu; Aaron S. Kesselheim
err分享
err收藏
Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018–2025: A cross-sectional analysis2018–2025年支持FDA批准抗癌药物的III期试验的偏倚风险与临床获益：一项横断面分析
errEuropean Journal of Cancer
IF7.1
err2026-06-25
err0
PREAI
errGuanqiao Li; Yiwen Pu; Congzhou Chen; Aaron S. Kesselheim; Ariadna Tibau
err分享
err收藏
Orphan Designation for Drugs Approved in the United States and European Union: A Comparative Analysis美国和欧洲联盟批准药物的罕见病药物认定：一项比较分析
errCLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
err2026-05-31
err0
PREAI
errEnrico Costa; Joseph S. Ross; Aaron S. Kesselheim
err分享
err收藏
What Utah’s clinical AI sandbox reveals about independent oversight犹他州的临床AI沙箱揭示了独立监督
errNature Medicine
IF50
err2026-05-27
err0
PREAI
errRahul Gorijavolu; Nikhil Jaiswal; Aaron S. Kesselheim; Joseph V. Sakran; Tina Hernandez-Boussard; Leo Anthony Celi
err分享
err收藏
Post-Approval Pediatric Use of Drugs Granted Waivers from Pediatric Testing已获豁免儿科测试的药物的批准后儿科使用
errCLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
err2026-05-15
err0
PREAI
errIan T.T. Liu; Timothy J. Savage; Theodore N. Tsacogianis; Aaron S. Kesselheim; Ameet Sarpatwari
err分享
err收藏
Clinical implementation of multi-cancer early detection tests: can we find a path forward?多癌种早期检测测试的临床实施：我们能否找到前进的道路？
errNature Reviews Clinical Oncology
IF82.2
err2026-05-14
err0
PREAI
errAriadna Tibau; Aaron S. Kesselheim
err分享
err收藏
Deeming Decisions, Delayed Drugs: How Foreign Reliance Distracts from Canada’s Real Drug Delays认定决定，延迟药物：外国依赖如何分散对加拿大实际药物延迟的注意力
errHealth Policy
IF3.4
err2026-04-15
err0
PREAI
errDaniel Eisenkraft Klein; Aaron S. Kesselheim
err分享
err收藏
Relevant Industry Payments to 2023–2024 Voting Members of the Advisory Committee on Immunization Practices相关行业向免疫实施咨询委员会2023–2024年投票成员的付款
errJournal of General Internal Medicine
IF4.2
err2026-03-23
err0
PREAI
errJonathan D. Alpern; Aaron S. Kesselheim
err分享
err收藏
Risk of neutropenia-related hospitalisation among clozapine initiators氯氮平起始用药者中与中性粒细胞减少症相关的住院风险
errBMJ Mental Health
IF4.9
err2026-02-06
err0
errOAAI
errSarpatwari, Ameet; Mahesri, Mufaddal; Lii, Joyce; Lee, Su Been; Zakoul, Heidi; Toyserkani, Gita A.; Zhou, Esther H.; Lacivita, Cynthia; Dal Pan, Gerald J.; Bykov, Katsiaryna; Moran, Lauren; Avorn, Jerry; Kesselheim, Aaron S.; Huybrechts, Krista F.
err分享
err收藏
Priority without progress: the FDA's neglected tropical disease voucher program after 18 years优先但不进步：美国食品药品监督管理局（FDA）忽视热带病凭证计划实施18年后的现状
errHealth Affairs Scholar
IF0
err2026-02-01
err1
PREAI
errGoh, Maple; Outterson, Kevin; Kesselheim, Aaron S.
err分享
err收藏
Physician Awareness of FDA’s Relaxation of REMS-Required Laboratory Testing Requirements and Changes in Prescribing Practices During the COVID-19 Pandemic
errDrug Safety
IF3.8
err2026-01-28
err0
PREAI
errCatherine S. Hwang; Zhigang Lu; Massimiliano Russo; Heidi Zakoul; Gita A. Toyserkani; Esther H. Zhou; Cynthia LaCivita; Gerald J. Dal Pan; Aaron S. Kesselheim; Ameet Sarpatwari
err分享
err收藏
Global access to commercial CAR T-cell therapies: A cross-sectional study of health technology assessment across the G20
errBlood
IF23.1
err2026-01-20
err0
PREAI
errAlex Y. Ge; William B. Feldman; Martin F. Kaiser; Kai Rejeski; Gloria Iacoboni; Gaurav Narula; Jason Yongsheng Chan; Michael J. Dickinson; Aaron S. Kesselheim; Edward R. Scheffer Cliff
err分享
err收藏
Physician Perspectives on Real-World Evidence for Prescribing to Older Patients医生对针对老年患者处方的真实世界证据的看法
errJOURNAL OF PHARMACY PRACTICE
IF1.1
err2026-01-01
err0
PREAI
errRand, Leah Z.; Wang, Junyi; Woloshin, Steven; Wang, Shirley V.; Darrow, Jonathan J.; Kesselheim, Aaron S.
err分享
err收藏
Gabriele et al. replyGabriele等人的答复
errNature Biotechnology
IF41.7
err2025-12-02
err0
PREAI
errSarah M. E. Gabriele; Matthew J. Martin; Aaron S. Kesselheim; S. Sean Tu
err分享
err收藏
Generic Liraglutide - Overlooked but Not Forgotten通用利拉鲁肽 - 被忽视但未被遗忘
errNEW ENGLAND JOURNAL OF MEDICINE
IF78.5
err2025-12-01
err0
PREAI
errGondi, Suhas; Kesselheim, Aaron S.; Rome, Benjamin N.
err分享
err收藏
Serial patent litigation: an emerging strategy to delay entry of generic competition系列专利诉讼：一种延缓仿制药竞争进入的新兴策略
errHealth Affairs Scholar
IF0
err2025-12-01
err0
errOAAI
errBonis, Timothy; Kesselheim, Aaron S.; Tu, Sean
err分享
err收藏
Prescription Drugs Subject to a Risk Evaluation and Mitigation Strategy: Patient Perspectives on Risk Communication and the Value of Educational Materials根据风险评估与缓解策略的处方药：患者对风险沟通和教育材料价值的看法
errDrug Safety
IF3.8
err2025-11-27
err0
PREAI
errSusan Chimonas; Carol Cosenza; Aaron S. Kesselheim; Gita A. Toyserkani; Kate Heinrich Oswell; Cynthia LaCivita; Gerald J. Dal Pan; Ameet Sarpatwari
err分享
err收藏

研究方向

暂无研究方向
合作学者
合作期刊
H
Hagop M. Kantarjian
H 指数: 230 · 论文数: 5.5K
A
Aziz Sheikh
H 指数: 177 · 论文数: 2.0K
G
George Perry
H 指数: 152 · 论文数: 1.5K
D
David W. Bates
H 指数: 147 · 论文数: 1.3K
R
Razelle Kurzrock
H 指数: 144 · 论文数: 2.3K
查看更多